

## **Pfizer Support to European and International Patient Organisations based in Belgium & Luxembourg in 2017**

Please note that all information in this document is also disclosed in the overall report on Pfizer Support to European and International Patient Organisations based in Europe in 2017 [here](#).

### **Support to European organisations**

The below list contains information on the support Pfizer has provided to European-level patient organisations based in Belgium & Luxembourg in 2016, and services contracted from them (e.g. speaker fees), and to national and global patient organisations for European-level work.

<b>European Cancer Patient Coalition E.C.P.C (BE0818999605)</b>							
<p><b>Organisation Description</b> Established in 2003, the European Cancer Patient Coalition is the voice of the European cancer patient community, uniquely representing the interests of all cancer patient groups from the most common to the rarest forms of cancer.</p>							
<p><b>Funding</b></p> <table border="1"> <tr> <td>€20,000</td> <td>Pfizer Inc provided support for development of a White paper on the condition of informal carers for people with cancer.</td> </tr> <tr> <td>€15,000</td> <td>Pfizer Inc provided support for ECPC's 2017 Annual General Meeting in Brussels.</td> </tr> <tr> <td>€62,000</td> <td>Pfizer Inc provided advanced support for the ECPC's Immuno-Oncology Portal in 2017. Payment initiated in 2016 and received by the organization in 2017.</td> </tr> </table>		€20,000	Pfizer Inc provided support for development of a White paper on the condition of informal carers for people with cancer.	€15,000	Pfizer Inc provided support for ECPC's 2017 Annual General Meeting in Brussels.	€62,000	Pfizer Inc provided advanced support for the ECPC's Immuno-Oncology Portal in 2017. Payment initiated in 2016 and received by the organization in 2017.
€20,000	Pfizer Inc provided support for development of a White paper on the condition of informal carers for people with cancer.						
€15,000	Pfizer Inc provided support for ECPC's 2017 Annual General Meeting in Brussels.						
€62,000	Pfizer Inc provided advanced support for the ECPC's Immuno-Oncology Portal in 2017. Payment initiated in 2016 and received by the organization in 2017.						
<b>European Federation of Neurological Associations (EFNA) - BE0543319269</b>							
<p><b>Organisation Description</b> The European Federation of Neurological Associations (EFNA) brings together European umbrella organisations of neurological patient advocacy groups, to work with other associations in the field of neurology, in what has been termed a 'Partnership for Progress'. EFNA engages in activities, which contribute to the advancement of neurology and related areas with a view to improving the quality of life of people living with neurological conditions, their families and carers.</p>							
<p><b>Funding</b> Pfizer Inc provided the following support:</p> <ul style="list-style-type: none"> <li>• €20.000 to support EFNA's advocacy activities.</li> <li>• €75.000 to support EFNA's Key note policy projects</li> </ul>							
<b>European Haemophilia Consortium (EHC) - BE0887106966</b>							
<p><b>Organisation Description</b> The European Haemophilia Consortium (EHC) is a European patient group representing national member organisations from 43 countries in Europe including members in all 28 Member States. The EHC is working to reduce the burden of the disease on both the individual and on society. Its mission is to improve the quality of life of people with Haemophilia in Europe.</p>							
<p><b>Funding</b> Pfizer Inc provided €60,000 to support the EHC 2017 CONSORTIUM.</p>							

**European Patients' Forum (EPF) - BE0807605667****Organisation Description**

The European Patients' Forum (EPF) is the umbrella patients' organisation at EU level. It brings together a broad range of leading European and national patients' organisations in different disease areas. Representing over 150 million patients, the EPF is a key interlocutor with European institutions, and promotes patients' rights, participation and involvement in EU healthcare developments.

**Funding**

€25,000	Pfizer Inc provided a grant support to EFF's Capacity Building Programme (payment initiated by Pfizer in 2016, received by EPF in 2017).
€25,000	Pfizer Inc provided a grant support to EFF's Capacity Building Programme for 2017.

**Pain Alliance Europe (PAE) - BE0843498142****Funding**

Pfizer Inc. provided €12.500 for Advocacy and Awareness Activities.

**The Synergist (BE0536681303)****Pfizer Inc. provided the following support:**

- €100.000 for the Patient Focused Medicines Development initiative 2016 (payment initiated in 2016 but completed in 2017)
- €100.000 for the Patient Focused Medicines Development initiative 2017

## **Appendix: Funding to organisations engaged in some work with patients.**

Pfizer provides funding to a number of organisations that are not patient organisations, but which have patient organisation membership or are otherwise relevant to patients. As such, they are listed here for the sake of transparency.

**European Alliance for Personalised Medicine (EAPM):** Founded in 2012, The European Alliance for Personalised Medicine (EAPM) brings together Europe's leading healthcare experts, healthcare organisations and institutions, and patient advocates to improve patient care by accelerating the development, delivery and uptake of personalised healthcare including personalised medicine and diagnostics. EAPM is based in Belgium. In 2017, Pfizer Inc. paid €25,000 to cover annual membership fees for 2017.

**European Brain Council (EBC):** The European Brain Council (EBC) is a coordinating council formed by European organisations in neurology, neurosurgery, psychiatry, basic brain research (neuroscience), as well as patient organisations and companies from within the pharma and biotech industries. It represents a vast network of patients, doctors and scientists, and these stakeholders along with its industrial partners make it eminently suited to work in close partnership with the European Parliament and Commission, national governments as well as other policy making bodies. EBC is based in Belgium. In 2017 Pfizer Ltd provided EBC with €20,000 as an annual membership fee.